2-(Methylamino)ethanol
Based on 1 Customer Validation
2-(Methylamino) ethanol (N-Methylethanolamine) is an orally active Phospholipase D inhibitor and analog of Ethanolamine (HY-Y0524). 2-(Methylamino) ethanol reduces the mRNA levels of ACE, ppET-1 and ECE-1, and inhibits MMP-2 activity. 2-(Methylamino) ethanol inhibits Collagen synthesis. 2-(Methylamino) ethanol attenuates ventricular hypertrophy, prevents increased myocardial stiffness and hemodynamic deterioration. 2-(Methylamino) ethanol can capture industrial acid gases and react with carbon dioxide to form carbamates and bicarbonates. 2-(Methylamino) ethanol can be used in studies related to hypertensive heart failure (diastolic heart failure).
For research use only. We do not sell to patients.
- Purity : 99.86%
- CAS No.: 109-83-1
- Formula: C3H9NO
- Molecular Weight:75.11
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Phospholipase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
MMP-2 |
Phospholipase D |
In Vitro
2-(Methylamino) ethanol (1-3 mM; 18 h) reduces PLD activity in Detroit-551 skin fibroblasts in a dose-dependent manner, with a significant reduction observed at 3 mM[1].
2-(Methylamino) ethanol (1-3 mM; 48 h) inhibits collagen synthesis in Detroit-551 skin fibroblasts in a dose-dependent manner, with significant inhibitory effects observed at concentrations of 1 mM and 3 mM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Detroit-551 (ATCC CCL 110) human skin fibroblasts
-
Concentration:1 mM, 3 mM
-
Incubation Time:48 h
-
Result:Increased MMP-1 production to ~750 ng/mL at 1 mM, a non-significant change compared to the control.
Increased MMP-1 production to ~1050 ng/mL at 3 mM, a statistically significant increase compared to both the control and the 1 mM dose (p < 0.05 vs. 0 mM; p < 0.05 vs. 1 mM).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dahl salt-sensitive (male, 8 weeks old at treatment start, fed 8% NaCl from 7 weeks to induce hypertensive heart failure); Wistar (male, toxicity cohort)[1]
-
Dosage:200 mg/kg/day (hypertensive heart failure model); 400 mg/kg/day (toxicity cohort)
-
Administration:p.o.; daily; 11 weeks (Dahl salt-sensitive rats); p.o.; daily; 2 weeks (Wistar rats)
-
Result:Normalized left ventricular end-diastolic pressure to control levels.
Normalized lung weight/tibial length to control levels.
Decreased PLD activity to 46% of control levels.
Reduced LV hydroxyproline concentration from 4.2 μmol/g to 2.7 μmol/g.
Lowered LV area of fibrosis from 10.5% to 4.5%.
Reduced LV mass/tibial length from 31.1 mg/mm to 26.0 mg/mm.
Reduced LV myocyte diameter from 23.8 μm to 22.6 μm.
Decreased mRNA levels of collagen type I, collagen type III, ACE, ppET-1, and ECE-1.
Reduced 72 kDa gelatinase (MMP-2) activity.
Did not significantly reduce systolic blood pressure.
Resulted in a mean body weight of 339 g in Wistar rats (vs. 366 g in controls).
Reduced alanine aminotransferase to 27 mU/mL in Wistar rats (vs. 53 mU/mL in controls).
Reduced alkaline phosphatase to 380 mU/mL in Wistar rats (vs. 533 mU/mL in controls).
Increased total protein to 7.38 g/dL in Wistar rats (vs. 6.67 g/dL in controls).
Increased albumin to 3.47 g/dL in Wistar rats (vs. 2.98 g/dL in controls).
Chemical Information
-
CAS No. 109-83-1
-
Appearance Liquid (Density: 0.935 g/cm3)
-
Molecular Weight 75.11
-
Formula C3H9NO
-
Color Colorless to light yellow
-
SMILES
CNCCO
-
Synonyms
N-Methylethanolamine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 200 mg/mL (2662.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (66.57 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (66.57 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (782 KB)
- English - EN (782 KB)
- Français - FR (782 KB)
- Deutsch - DE (782 KB)
- Norwegian - NO (782 KB)
- Español - ES (782 KB)
- Swedish - SV (782 KB)
- Italian - IT (782 KB)
- Korean - KR (782 KB)
- Portuguese - PT (782 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 13.3138 mL | 66.5690 mL | 133.1381 mL | 332.8452 mL |
| 5 mM | 2.6628 mL | 13.3138 mL | 26.6276 mL | 66.5690 mL | |
| 10 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL | 33.2845 mL | |
| 15 mM | 0.8876 mL | 4.4379 mL | 8.8759 mL | 22.1897 mL | |
| 20 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL | 16.6423 mL | |
| 25 mM | 0.5326 mL | 2.6628 mL | 5.3255 mL | 13.3138 mL | |
| 30 mM | 0.4438 mL | 2.2190 mL | 4.4379 mL | 11.0948 mL | |
| 40 mM | 0.3328 mL | 1.6642 mL | 3.3285 mL | 8.3211 mL | |
| 50 mM | 0.2663 mL | 1.3314 mL | 2.6628 mL | 6.6569 mL | |
| 60 mM | 0.2219 mL | 1.1095 mL | 2.2190 mL | 5.5474 mL | |
| 80 mM | 0.1664 mL | 0.8321 mL | 1.6642 mL | 4.1606 mL | |
| 100 mM | 0.1331 mL | 0.6657 mL | 1.3314 mL | 3.3285 mL |
2-(Methylamino)ethanol Related Classifications
HY-Y1783 Related Classifications
Powered by Bioz
Keywords
- 2-(Methylamino)ethanol
- 109-83-1
- N-Methylethanolamine
- Phospholipase
- Drug Derivative
- Angiotensin-converting Enzyme (ACE)
- Endothelin Receptor
- MMP
- Collagen
- Biochemical Assay Reagents
- hypertensive heart failure
- Wistar rats
- collagen synthesis
- phospholipase D
- ventricular hypertrophy
- Detroit-551 human skin fibroblasts
- MMP-2
- cardiac fibrosis
- collagenase
- myocardial stiffening
- Inhibitor
- inhibitor
- inhibit